Drug Profile


Alternative Names: GS-6615

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antiarrhythmics; Ischaemic heart disorder therapies; Pyrimidines; Small molecules; Vasodilators
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Long QT syndrome
  • Phase II/III Hypertrophic cardiomyopathy
  • Phase II Ventricular arrhythmias
  • No development reported Ischaemic heart disorders

Most Recent Events

  • 01 Oct 2016 Gilead Sciences completes a phase II trial in Ventricular arrhythmias in USA, Canada, Czech Republic, Denmark, Germany, Hungary, Israel, the Netherlands and Poland(PO) (NCT02104583)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Ischaemic-heart-disorders(In volunteers) in USA (PO, Tablet)
  • 01 Jun 2016 Gilead Biosciences completes a phase I trial for Long QT syndrome type 2 in USA (NCT02365506)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top